Omega-3 Fatty Acid Status Enhances the Prevention of Cognitive Decline by B Vitamins in Mild Cognitive Impairment
Oulhaj A, Jernerén F, Refsum H, Smith AD, de Jager CA
Journal of Alzheimer's disease : JAD · 105 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Norges Forskningsråd
- Organización sin fines de lucro
- Norman Collisson Foundation
- Gobierno
- Medical Research Council
Según 3 financiadores declarados.
Publicación
- Publicado
- 2016-01-22 · J Alzheimers Dis · vol. 50 · número 2 · págs. 547–557
- Editorial
- IOS Press
- Citado
- 159 citas · más que el 99% de estudios similares · 15.8× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 45 trabajos
- Acceso
- Acceso abierto (revista híbrida) · OTHER-OA
- Áreas de investigación
- Dementia and Cognitive Impairment Research · Fatty Acid Research and Health · Folate and B Vitamins Research
- Palabras clave
- omega-3 fatty acids, docosahexaenoic acid
- MeSH
- humans, disease progression, fatty acids, omega-3, vitamin b complex, treatment outcome, cognition, neuropsychological tests, aged, aged, 80 and over, female, male, cognitive dysfunction
5 autores
- Abderrahim Oulhaj🇦🇪 · autor de correspondenciaUnited Arab Emirates University
- Fredrik Jernerén🇬🇧University of Oxford
- Helga Refsum🇳🇴🇬🇧University of Oslo; University of Oxford
- A. David Smith🇬🇧University of Oxford
- Celeste A. de Jager🇿🇦 · autor de correspondenciaUniversity of Cape Town
Resumen
El texto original del estudio, en el idioma en que se publicó.
A randomized trial (VITACOG) in people with mild cognitive impairment (MCI) found that B vitamin treatment to lower homocysteine slowed the rate of cognitive and clinical decline. We have used data from this trial to see whether baseline omega-3 fatty acid status interacts with the effects of B vitamin treatment. 266 participants with MCI aged ≥70 years were randomized to B vitamins (folic acid, vitamins B6 and B12) or placebo for 2 years. Baseline cognitive test performance, clinical dementia rating (CDR) scale, and plasma concentrations of total homocysteine, total docosahexaenoic and eicosapentaenoic acids (omega-3 fatty acids) were measured. Final scores for verbal delayed recall, global cognition, and CDR sum-of-boxes were better in the B vitamin-treated group according to increasing baseline concentrations of omega-3 fatty acids, whereas scores in the placebo group were similar across these concentrations. Among those with good omega-3 status, 33% of those on B vitamin treatment had global CDR scores >0 compared with 59% among those on placebo. For all three outcome measures, higher concentrations of docosahexaenoic acid alone significantly enhanced the cognitive effects of B vitamins, while eicosapentaenoic acid appeared less effective. When omega-3 fatty acid concentrations are low, B vitamin treatment has no effect on cognitive decline in MCI, but when omega-3 levels are in the upper normal range, B vitamins interact to slow cognitive decline. A clinical trial of B vitamins combined with omega-3 fatty acids is needed to see whether it is possible to slow the conversion from MCI to AD.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.